Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lonigutamab in Thyroid Eye Disease (TED)
NCT05683496Phase 2Completed
- Sponsor
- Acelyrin
- Start
- Feb 2023
- Primary completion
- May 2025
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 2 trial of lonigutamab in thyroid eye disease (TED), sponsored by Acelyrin. Started Feb 2023; status: completed.
02
Drugs
lonigutamab
03
Conditions
thyroid eye disease (TED)
Beyond the preview
Go deeper on NCT05683496.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05683496.